Education
About Us
Working with TipRanks
Follow Us
Addex Therapeutics (ADXN)
NASDAQ:ADXN
ADXN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.51 - $13.27
Previous CloseN/A
Volume26.36K
Average Volume (3M)12.19K
Market Cap
$14.23M
Enterprise Value$8.17M
Total Cash (Recent Filing)$2.83M
Total Debt (Recent Filing)CHF40.20K
Price to Earnings (P/E)0.8
Beta0.34
Next Earnings
Sep 01, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,536,287
10 Day Avg. Volume15,497
30 Day Avg. Volume12,186
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.71
Price to Sales (P/S)0.00
P/FCF Ratio-2.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.00Price Target Upside0.00%
Rating ConsensusHold
Number of Analyst Covering0
Addex Therapeutics News
PremiumCompany Announcements
Addex Therapeutics Reports Q1 2025 Financial Results
PremiumCompany Announcements
Addex Therapeutics Earnings Call: Strategic Gains Amid Financial Challenges
PremiumCompany Announcements
Addex Therapeutics Reports Strong 2024 Financial Turnaround
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.07% Other Institutional Investors
99.93% Public Companies and
Individual Investors
ADXN FAQ
What was Addex Therapeutics’s price range in the past 12 months?
Addex Therapeutics lowest stock price was $6.51 and its highest was $13.27 in the past 12 months.
What is Addex Therapeutics’s market cap?
Addex Therapeutics’s market cap is $14.23M.
When is Addex Therapeutics’s upcoming earnings report date?
Addex Therapeutics’s upcoming earnings report date is Sep 01, 2025 which is in 46 days.
How were Addex Therapeutics’s earnings last quarter?
Currently, no data Available
Is Addex Therapeutics overvalued?
According to Wall Street analysts Addex Therapeutics’s price is currently same.
Does Addex Therapeutics pay dividends?
Addex Therapeutics does not currently pay dividends.
What is Addex Therapeutics’s EPS estimate?
Addex Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Addex Therapeutics have?
Addex Therapeutics has 1,536,287 shares outstanding.
What happened to Addex Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Addex Therapeutics?
Among the largest hedge funds holding Addex Therapeutics’s share is New Leaf Venture Partners, L.L.C.. It holds Addex Therapeutics’s shares valued at 0.
Company Description
Addex Therapeutics
Addex Therapeutics (ADXN) is a clinical-stage pharmaceutical company focused on the development of innovative oral small molecule drugs for neurological disorders. The company operates primarily in the biotechnology and pharmaceuticals sector, with a core emphasis on allosteric modulation-based therapies. Addex Therapeutics is engaged in developing a pipeline of compounds targeting central nervous system disorders, including Parkinson's disease, epilepsy, and other neurodegenerative and psychiatric conditions.
ADXN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant strategic partnerships and advancements in drug development programs, notably the successful Series A financing for Neurosterix and progress in the GABAB PAM program. However, challenges remain with decreased income and cash limitations for unpartnered programs, indicating a balanced outlook.Read More>